EBS - Emergent Biosolutions Non-GAAP EPS of -$0.86 misses by $1.26 revenue of $242.7M misses by $25.66M
- Emergent Biosolutions press release ( NYSE: EBS ): Q2 Non-GAAP EPS of -$0.86 misses by $1.26 .
- Revenue of $242.7M (-38.9% Y/Y) misses by $25.66M .
- FY2022 Outlook : Total revenues of $1.15B to $1.25B vs. consensus of $1.21B; Adjusted net income of -$15M to $10M.
-
The company is also providing a forecast for Q3 2022 total revenues of $230M - $270M vs. consensus of $294.03M
For further details see:
Emergent Biosolutions Non-GAAP EPS of -$0.86 misses by $1.26, revenue of $242.7M misses by $25.66M